Colorectal cancer (CRC) is a common cancer with substantial mortality. A significant proportion of CRC arises from preexisting colorectal adenomas (CAA; polyps) through the adenoma--carcinoma sequence. In this sequence, a stepwise pattern of genetic changes drive normal colonic epithelium to invasive cancer. Many deaths could be avoided if precancerous adenomas or early-stage cancers could be identified and treated prior to the development of more advanced malignancy ([@bib58]; [@bib86]). Current screening tools for detection of CRC include colonoscopy, faecal-based tests (occult blood testing and DNA-based stool tests), and plasma-based assays. As these methods each have disadvantages, including morbidity ([@bib44]), low sensitivity and specificity ([@bib31]), expense ([@bib6]), and poor patient compliance ([@bib43]), there is need for a more accurate, less invasive screening tool to permit early detection and intervention.

Biological markers or biomarkers are defined as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention\' ([@bib59]). Biomarkers, such as blood, urine, and cerebrospinal fluid, can be used for screening, diagnosis, and predicting prognosis in human diseases ([@bib50]). Plasma and serum are components of blood and are commonly used in diagnostic assays. Serum is of similar composition to plasma except for lacking clotting factors. Both plasma and serum contain hormones, glucose, electrolytes, antibodies, antigens, and nutrients making them ideal media in diagnostic testing ([@bib49]). The most commonly used blood-based CRC biomarker, carcinoembryonic antigen, which is used for postoperative surveillance and for monitoring response to therapy, lacks sensitivity and specificity for screening or for the detection of recurrent CRC ([@bib18]).

microRNAs (miRNAs) are small, non-protein-coding RNA molecules that regulate gene expression by complementary binding to the 3′ untranslated region of target mRNA. They cause target degradation, translational repression, or gene silencing and thus affect subsequent protein expression. miRNAs exhibit important regulatory functions related to cell differentiation, development, and growth ([@bib52]; [@bib14]). They have also been shown to be dysregulated in a number of cancers, including CRC, by influencing oncogenes and tumour-suppressor genes ([@bib87]; [@bib12]). miRNAs have been identified in body fluids, such as plasma, saliva, urine, and faeces ([@bib11]). They have been shown to be actively released from cells in microvesicles, exosomes, or bound to proteins. miRNAs are inherently stable accounting for the emerging use as potential biomarkers for human disease and as targets for disease intervention ([@bib35]; [@bib54]).

The purpose of this systematic review and meta-analysis is to assess published studies describing the use of plasma- or serum-based miRNAs as biomarkers for the diagnosis of CRC, to assess the accuracy of these miRNAs as biomarkers, and to identify those miRNAs for which there is the most evidence of potential use as a specific and sensitive blood-based assay for the diagnosis of CRC.

Materials and methods
=====================

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines ([@bib47]; [@bib57]). Two reviewers (JC, NG) were independently involved with study selection, data extraction, and quality assessment.

Study selection
---------------

An electronic search of PubMed (NCBI, Bethesda, MD, USA) and EMBASE (Elsevier, Amsterdam, The Netherlands) databases was performed for relevant articles published between January 2002 and April 2016 using the following medical subject heading terms: ('plasma\' OR 'serum\') AND ('microRNA\' OR 'miRNAs\' OR 'miR\*\') AND ('colorectal cancer\' OR 'colorectal carcinoma\' OR 'colon cancer\' OR 'colorectal adenoma\'). This time period was based on a preliminary search that revealed no serum or plasma miRNA studies in patients with CRC undertaken prior to 2002. A grey literature search of meeting proceedings and abstracts was performed to detect any relevant unpublished work ([@bib47]). Meeting proceedings from the following organisations were searched for abstracts relevant to plasma miRNA and CRC for the period 2010 and 2016: American Society for Clinical Oncology, the American Society of Colon and Rectal Surgeons, the American Association for Cancer Research, and the Society for Surgical Oncology.

No language restrictions were imposed. Duplicates were removed. Based on the title and abstract, manuscripts of interest were obtained for full-text review. Only full-text manuscripts were included. Additional articles were identified by manually searching the references of original and review articles.

Inclusion and exclusion criteria
--------------------------------

Inclusion and exclusion criteria were developed by the investigative team. Human studies investigating plasma- or serum-based miRNAs as a method for diagnosis of CRC using patients with CRC as compared with healthy controls were included. Studies evaluating treatment response were excluded, as were studies evaluating tissue miRNA or miRNA in other body fluids. The primary outcome measure was determination of significantly dysregulated serum or plasma miRNA in patients with CRC as compared with healthy controls.

Data extraction, meta-analysis, and quality assessment
------------------------------------------------------

Each manuscript was assessed independently by two investigators (JC and NG). Disagreements among reviewers were resolved by consensus. Data extracted included the following: authors, publication year, country, type of blood-based fluid (serum or plasma), characteristics of the study population (both case and control), study design (qRT-PCR detection method), whether miRNA screening was performed, number of miRNAs assessed, listing of the specific dysregulated miRNAs in patients with CRC as compared with controls, and outcome of statistical analyses including details of miRNA analysis, such as type of reference miRNA utilised. Studies reporting on single miRNA were included in the meta-analysis and were evaluated according to the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) checklist ([@bib78]). QUADAS-2 is designed to assess the risk of bias and applicability of studies of diagnostic accuracy. It consists of four domains: patient selection, index test, reference standard, and flow and timing. Each is assessed with respect to the risk of bias and the first three domains assessed with respect to applicability.

Statistical analysis
--------------------

Analysis was based on the accuracy of the identified miRNAs to diagnose the presence of CRC as determined using Receiver Operator Characteristic (ROC) curves as Area Under the Curve (AUC) value and sensitivity and specificity, where available ([@bib7]). Studies that identified the sensitivity and specificity of individual miRNA in diagnosing CRC were included in the meta-analysis. Owing to the presumed heterogeneity of studies, a random-effects model (DerSimonian--Laird method) was used ([@bib47]). Forest plots were constructed using STATA version 11 (StataCorp LP, College, Station, TX, USA). The heterogeneity of included studies was assessed using *I*^2^ and *χ*^2^ statistics and was judged to be significant if *I*^2^ was \>50% or *P*\<0.05. Sensitivity analyses were performed for (1) studies judged to have low risk and low concern following QUADAS-2 assessment (see above), (2) based upon the type of sample used (i.e., plasma or serum), (3) the method of qRT-PCR detection (TaqMan or SYBR Green), and (4) the type of reference control used for normalisation (internal or external).

Results
=======

Three hundred and ninety-nine records from the database search and 3 from the grey literature were initially identified ([Figure 1](#fig1){ref-type="fig"}); 282 records remained after duplicates were removed and a further 190 were considered not relevant to the review topic. Ninety-two records were screened, and after abstract review, 33 were subsequently excluded owing to a lack of reporting on miRNA, results using cancers other than CRC, non-human subjects, and/or inability to obtain full abstracts or articles. Full-text articles were obtained for the remaining 59 articles that were deemed relevant. A further 25 articles were excluded for the following reasons: review article (*n*=14), abstract only (*n*=2), not plasma or serum (*n*=1), not diagnostic (*n*=5), and not CRC (*n*=3). Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included for the final systematic review ([@bib60]; [@bib30]; [@bib64]; [@bib2]; [@bib35]; [@bib73]; [@bib75]; [@bib5]; [@bib23]; [@bib28]; [@bib36]; [@bib42]; [@bib46]; [@bib70]; [@bib83]; [@bib88]; [@bib3]; [@bib16]; [@bib63]; [@bib79]; [@bib85]; [@bib89]; [@bib4]; [@bib10]; [@bib19]; [@bib22]; [@bib27]; [@bib65]; [@bib76]; [@bib39]; [@bib40]; [@bib68]; [@bib77]; [@bib84]) and of these 19 were included in the meta-analysis ([@bib60]; [@bib30]; [@bib64]; [@bib35]; [@bib73]; [@bib75]; [@bib42]; [@bib70]; [@bib88]; [@bib3]; [@bib16]; [@bib79]; [@bib4]; [@bib10]; [@bib19]; [@bib40]; [@bib68]; [@bib77]; [@bib84]). Of these 34 studies, 20 (59%) used plasma ([@bib60]; [@bib30]; [@bib64]; [@bib2]; [@bib35]; [@bib75]; [@bib23]; [@bib36]; [@bib46]; [@bib88]; [@bib16]; [@bib63]; [@bib79]; [@bib85]; [@bib10]; [@bib19]; [@bib22]; [@bib76]; [@bib40]; [@bib68]) and 14 (41%) used serum samples ([@bib73]; [@bib5]; [@bib28]; [@bib42]; [@bib70]; [@bib83]; [@bib3]; [@bib89]; [@bib4]; [@bib27]; [@bib65]; [@bib39]; [@bib77]; [@bib84]). Studies were conducted in North America, South East Asia, or Europe. Study characteristics are shown in [Table 1](#tbl1){ref-type="table"}.

A total of 6010 patients were included; 3454 CRC patients, and 2556 healthy controls. Seven studies also included evaluation of 420 patients with CAA, the precursor lesion to CRC. From the studies that reported patient demographics, 1792 men and 1410 women were included among CRC cases and 1198 men and 942 women were included among healthy controls ([Table 1](#tbl1){ref-type="table"}).

All patients included in this review had the diagnosis of CRC confirmed by histopathology. Patients were excluded from individual studies if they had a diagnosis of familial adenomatous polyposis, hereditary non-polyposis CRC or other inflammatory condition or if they received preoperative radiotherapy or chemotherapy. Of the 19 studies included in meta-analysis, 18 studies staged CRC according to either the American Joint Committee on Cancer or the Union for International Cancer Control Tumor-Node-Metastasis staging system. The remaining study staged CRC cases according to the Dukes\' classification system.

Identification of dysregulated miRNAs in the plasma or serum
------------------------------------------------------------

Sixteen of the 34 studies performed miRNA screening studies ([@bib60]; [@bib2]; [@bib35]; [@bib75]; [@bib5]; [@bib23]; [@bib28]; [@bib36]; [@bib46]; [@bib89]; [@bib79]; [@bib22]; [@bib27]; [@bib76]; [@bib39]; [@bib68]) in order to identify dysregulated miRNAs in the plasma or serum of CRC cases compared with healthy controls, whereas the remaining 18 studies identified miRNAs for assessment based on the literature or based on their own prior studies ([@bib30]; [@bib64]; [@bib73]; [@bib42]; [@bib83]; [@bib70]; [@bib88]; [@bib3]; [@bib16]; [@bib63]; [@bib85]; [@bib4]; [@bib10]; [@bib19]; [@bib65]; [@bib40]; [@bib77]; [@bib84]). A total of 617 miRNAs were differentially expressed between CRC and healthy controls in these screening studies, and of these, 69 miRNAs were found to be significantly dysregulated in validation or subsequent studies. A further 36 miRNAs were shown to have either increased or decreased expression in CRC, but no statistical analyses were performed ([@bib2]; [@bib28]) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Significantly dysregulated miRNAs in the plasma or serum of CRC cases
---------------------------------------------------------------------

Thirty-one miRNAs were found to be either upregulated (*n*=17, miR-17-3p, miR-18a, miR-19a-3p, miR-20a, miR-21, miR-29a, miR-92, miR-96, miR-106a, miR-182, miR-200c, miR-206, miR-210, miR-221, miR-223-3p, miR-372, miR-378) ([@bib60]; [@bib30]; [@bib64]; [@bib35]; [@bib73]; [@bib5]; [@bib42]; [@bib70]; [@bib88]; [@bib3]; [@bib16]; [@bib63]; [@bib79]; [@bib85]; [@bib89]; [@bib10]; [@bib80]; [@bib39]; [@bib68]; [@bib77]; [@bib84]) or downregulated (*n*=14, miR-24, miR-26a-5p, miR-29b, miR-30b, miR-142-3p, miR-145, miR-194, miR-218, miR-320a, miR-375, miR-422a, miR-423-5p, miR-601, miR-760) ([@bib75]; [@bib83]; [@bib79]; [@bib89]; [@bib4]; [@bib19]; [@bib22]; [@bib27]; [@bib65]; [@bib39]; [@bib40]) in CRC cases as compared with controls ([Table 2](#tbl2){ref-type="table"}). Six upregulated miRNAs (miR-17-3p, miR-18a, miR-21, miR-29a, miR-92, miR-106a) and two downregulated miRNAs (miR-29b, miR-145) were identified by more than one study ([@bib60]; [@bib30]; [@bib35]; [@bib73]; [@bib5]; [@bib42]; [@bib70]; [@bib88]; [@bib3]; [@bib16]; [@bib85]; [@bib89]; [@bib4]; [@bib10]; [@bib65]; [@bib80]; [@bib39]; [@bib40]). miR-21 was the most frequently identified dysregulated miRNA ([@bib35]; [@bib73]; [@bib42]; [@bib70]; [@bib3]; [@bib16]; [@bib85]; [@bib80]).

Seven studies identified a two miRNA panel ([@bib30]; [@bib75]; [@bib23]; [@bib36]; [@bib42]; [@bib88]; [@bib79]), five studies identified a three miRNA panel ([@bib23]; [@bib19]; [@bib27]; [@bib76]; [@bib39]), and five studies identified a panel consisting of four or more miRNAs ([@bib2]; [@bib75]; [@bib23]; [@bib28]; [@bib46]) that was utilised in the diagnosis of CRC ([Table 2](#tbl2){ref-type="table"}).

Area under the curve, sensitivity, and specificity
--------------------------------------------------

The most common method of reporting diagnostic accuracy of dysregulated miRNAs was using AUC and sensitivity and specificity as determined from ROC curves. Of the identified miRNAs, AUC values ranged from 0.590 to 0.943, sensitivity ranged from 46% to 92.79% and specificity from 41% to 93.2%. The highest AUC, sensitivity, and specificity combination was reported for a panel of four miRNAs, miR-29a, miR-92a, miR-601, and miR-760 (AUC 0.943, sensitivity 83.3%, specificity 93.1%) ([@bib75]) ([Table 2](#tbl2){ref-type="table"}).

Quality assessment
------------------

Quality assessment results of the studies reporting upon single miRNA included in meta-analysis are shown in [Figures 2A and B](#fig2){ref-type="fig"} using the QUADAS-2 evaluation tool.

Meta-analysis
-------------

Studies that identified a single dysregulated miRNA in CRC cases compared with controls, along with the corresponding AUC and sensitivity and specificity for the identified miRNA, were included in the meta-analysis. Using these criteria, 28 individual miRNAs were identified in 19 studies ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The sensitivity (±95% confidence intervals (CIs)) and specificity (±95% CIs) for each miRNA are shown in the corresponding forest plots ([Figures 3A and B](#fig3){ref-type="fig"}). Overall sensitivity and specificity of the 28 individual miRNAs in the diagnosis of CRC were 76% (95% CI 72--80%) and 76% (95% CI 72--80%), respectively. These results indicate good discriminative ability of the use of miRNAs as biomarkers for the detection of CRC. Sensitivity analyses were performed for studies of good quality ([Figures 4A and B](#fig4){ref-type="fig"}), type of patient sample used (plasma *vs* serum, [Supplementary Figures S1a and b and S2a and b](#sup1){ref-type="supplementary-material"}), type of miRNA detection method (SYBR green *vs* TaqMan, [Supplementary Figures S3a and b and S4a and b](#sup1){ref-type="supplementary-material"}), and type of miRNA reference used for normalisation (internal *vs* external, [Supplementary Figures S5a and b and S6a and b](#sup1){ref-type="supplementary-material"}). Compared with the sensitivity and specificity obtained when including all studies, sensitivity analysis using only high-quality studies did not significantly alter sensitivity and specificity (77% *vs* 76% and 77% *vs* 76%, respectively). This was also true for the remaining sensitivity analyses, where there was no improvement in sensitivity or specificity.

Discussion
==========

This systematic review of 34 manuscripts that utilise plasma- or serum-based miRNAs in the diagnosis of CRC has identified 617 miRNAs reported to be dysregulated in 3454 cases of CRC as compared with 2556 healthy controls. A total of 31 single miRNAs were identified as significantly dysregulated between CRC cases and controls. Eight of the dysregulated miRNAs were identified and validated by more than one study; six were upregulated: miR-17-3p, miR-18a, miR-21, miR-29a, miR-92, and miR-106a and two were downregulated: miR-29b and miR-145. A further 23 significantly dysregulated miRNAs were identified by only one study. Conceptually, the increased expression of specific miRNAs in the presence of disease is accepted, assuming that the cancer is the source of the dysregulated miRNA export into the blood. However, the source of the miRNA dysregulation is not necessarily known, and miRNAs that are consistently downregulated only in the presence of disease should not necessarily be discounted as reliable biomarkers, provided there is an acceptable negative predictive value for the elevated levels of that miRNA in the absence of disease. This would, for example, be true of a miRNA whose target was a known oncogene.

Significant advances have occurred in the field of tumour-associated miRNAs since their first discovery in plasma ([@bib55]; [@bib11]) as the number of studies investigating their expression has markedly increased in recent years. Although colonoscopy remains the gold standard screening test for the diagnosis of CRC ([@bib58]; [@bib13]; [@bib86]; [@bib62]), the evaluation of miRNA within plasma and/or serum of circulating blood has provided a new area for biomarker research.

microRNAs are small, naturally occurring, non-protein-coding RNA that are transcribed in the nucleus as large RNA precursors called primary miRNAs (pri-miRNAs) ([@bib38]). These pri-miRNAs are enzymatically cleaved in the nucleus by the enzyme Drosha into precursor miRNA (pre-miRNA) ([@bib25]). The resulting approximately 70-nucleotide pre-miRNA are folded into stem-loop structures. These pre-miRNAs are then exported into the cytoplasm by the GTP-dependent transport protein exportin 5 ([@bib82]). Once in the cytoplasm, they undergo additional processing by the enzyme Dicer to generate the mature double-stranded miRNA approximately 22 nucleotides in length. Dicer also initiates the formation of the RNA-induced silencing complex (RISC) ([@bib24]). It is in this final part of miRNA biogenesis that the leading miRNA strand is incorporated into the RISC complex, which is then guided into the complementary 3′ or 5′ untranslated region of the target mRNA. The RISC is responsible for the gene silencing observed owing to miRNA expression and RNA interference ([@bib20]).

miRNAs are stable in extracellular fluid as they are protected from RNases by virtue of being bound to argonaute proteins ([@bib51]). Discovery of dysregulated miRNA expression has been identified in oesophageal, lung, liver, pancreatic, bladder, ovarian, and gastric cancers ([@bib12]). miRNAs have been identified in numerous body fluids, such as plasma, saliva, faeces, and urine, where they are actively released from cells within microvesicles, exosomes, or bound to proteins ([@bib35]; [@bib11]). These factors suggest that miRNAs can be used as biomarkers for cancer and other disease states ([@bib71]).

miRNAs can function as either tumour suppressors or oncogenes. Overexpression of miRNAs in cancer may function as oncogenes and promote oncogenesis by downregulating tumour suppressors or other genes involved in cell differentiation. In contrast, underexpressed miRNAs in cancer may function as tumour suppressors by inhibiting oncogenesis via downregulation of proteins with oncogenic qualities ([@bib87]; [@bib67]). The miR-17-92 cluster, also known as oncomiR-1 was the first miRNA oncogene to be described ([@bib41]). Six miRNAs form this miR-17-92 cluster: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1, and are known to be dysregulated in many cancers ([@bib56]). miR-17-92 has also been found to be overexpressed in both the tissue and serum of CRC patients ([@bib15]; [@bib60]). In our systematic review, five of the six members of this cluster, with the exception of miR-19b-1, were found to be significantly upregulated in the serum or plasma of CRC patients as compared with controls in eight studies ([@bib60]; [@bib30]; [@bib5]; [@bib42]; [@bib88]; [@bib89]; [@bib10]; [@bib39]). The most predictive miRNA was miR-92a, with AUC values ranging from 0.786 to 0.890, from 65.5% to 89% sensitivity, and from 70% to 82.5% specificity. The remaining member of the cluster, miR-19b-1, was also significantly upregulated in CRC patients when combined as a two miRNA panel together with miR-19a, with an AUC of 0.82, 78.57% sensitivity, and 77.36% specificity ([@bib23]). These data support the oncogenic role of the miR-17-92 cluster in CRC.

We identified seven different studies that demonstrated significant upregulation of miR-21 in CRC patients as compared with healthy controls. [@bib35] identified miR-21 as a biomarker for CRC. Validated CRC tissue miRNAs were evaluated in a plasma test set consisting of 30 CRC patients and 30 healthy controls. The most dysregulated tissue miRNAs were then validated in different cohort of 20 CRC patients with 20 age- and race-matched subjects without CRC. In the plasma test group, miR-21 differentiated CRC patients from controls with AUC 0.910 and 90% specificity and sensitivity ([@bib35]). Following this, 6 groups reproduced similar results with AUCs ranging from 0.647--0.927, 65--87.5% sensitivity, and 74.4--93.2% specificity. Although these data were promising, dysregulation of miR-21 has also been described in many other cancers ([@bib9]; [@bib33]; [@bib72]; [@bib34]; [@bib45]; [@bib53]; [@bib69]; [@bib29]). There is therefore need for a plasma miRNA profile specific for CRC.

miR-29a is another miRNA that has been reported to be upregulated in CRC patients in three studies ([@bib30]; [@bib5]; [@bib80]). miR-29a is part of the miR-29 family (miR-29a, miR-29b, miR-29c). Interestingly, another member of the miR-29 family, miR-29b, was observed to be downregulated in CRC compared with control subjects in two studies ([@bib4]; [@bib40]). Members of the miR-29 family exhibit differential regulation, implying that their functional relevance may not be identical ([@bib37]). miR-29b has been shown to function as a tumour suppressor in various cancers and diseases ([@bib81]), while miR-29a has been shown to act as a tumour suppressor in lung cancer ([@bib17]) but as an oncogene in CRC, ovarian, and breast cancer ([@bib21]; [@bib66]).

In order to reduce CRC-associated mortality, the ideal biomarker would be able to identify individuals with both early-stage CRC and its precursor lesion, the colorectal advanced adenoma (CAA), from healthy control subjects. CAA have previously been defined as adenomas with a villous component or with high-grade dysplasia \>0.75 cm size in diameter ([@bib8]). In the studies included in this review, seven studies evaluated miRNAs found to be significantly dysregulated in CRC patients and in 420 patients with a diagnosis of CAA. Five of these seven studies reported miRNA panels significantly upregulated in CAA as compared with healthy controls ([@bib30]; [@bib36]; [@bib42]; [@bib70]; [@bib89]). One study also identified a panel of 5 miRNAs that distinguished between CRC and CAA with AUC 0.856 ([@bib36]). The remaining two studies found no significant differences in miRNA profile between CAA and healthy controls ([@bib23]; [@bib46]) ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Commercially available non-invasive screening tests have recently been developed in an attempt to have the same detection accuracy of CRC compared with the current gold standard screening method of colonoscopy ([@bib1]; [@bib32]; [@bib48]; [@bib61]). These tests, both blood based and faecal based, measure validated markers of CRC and include DNA markers and gene expression profiles. To date, none have a good ability to detect the precursor to CRC, CAA. We have developed a plasma-based miRNA screening assay comprising of combinations of 7 miRNAs, which is able to detect any neoplasia from controls with AUC 0.91, colorectal neoplasia from other cancers with AUC 0.79, and CRC from CAA with AUC 0.98. In addition, our assay is able to differentiate CRC from controls with AUC 0.98, sensitivity 90%, and specificity 100%, CAA from controls with AUC 0.823, sensitivity 65%, and specificity 95%, and CRC and CAA from controls with AUC 0.835, sensitivity 80%, and specificity 85% ([@bib8]). This miRNA panel, although in its infancy, provides much promise in the development of a non-invasive screening test for detection of CRC.

Inevitably, studies included in the systematic review and meta-analysis will vary with regards to clinical characteristics, study design, and type of study, and these factors contribute sources of heterogeneity. Clinical characteristics of control subjects were often poorly defined. Of the individual studies included in the meta-analysis, five defined healthy controls by colonoscopic confirmed absence of CRC, including absence of adenomas. The remaining 14 studies defined healthy controls as having the absence of malignancy or inflammatory condition or a benign physical examination without other qualification or elaboration. Similarly, 11 studies reported no significant differences in age or sex between CRC cases and healthy controls, 5 reported to age-sex matching between cases and controls, and 3 did not comment on age-sex matching status.

There was significant heterogeneity of the studies included in this review (*I*^2^ 85.7% for sensitivity, and 76.5% for specificity, *P*\<0.001). Heterogeneity is expected in meta-analyses, one reason being differing sample sizes between studies ([@bib26]). Many of the studies included a relatively small number of participants. For the studies included in meta-analysis, the study populations ranged from 32 to 268 for CRC cases and from 30 to 400 for control cases. This may reflect the strict inclusion criteria adopted by investigators but potentially carries the risk of type I error. In future, studies with larger numbers of patients, along with different populations of patients in terms of genetics, geography and race, will increase the validity of our conclusions regarding the reliability of plasma miRNA assays. In addition, reference miRNA controls used varied between studies, with both internal and external miRNAs used for normalisation of results. This may account for the differing miRNAs identified. Similarly, miRNAs assessed were extracted from either plasma or serum samples. Some have reported differing miRNA concentrations depending on whether serum or plasma are used as the source material ([@bib74]). Unlike previous studies, miRNAs measured in the serum of patient samples yielded better results than for plasma in this review. Although there is little difference in composition between plasma and serum, for the development of a blood-based biomarker, a standard blood component is preferred. A limitation to this review is the validity of the results given the significant heterogeneity of the studies. We believe it is, however, still reasonable to interpret these results as the overwhelming majority of the studies trend towards high sensitivity and specificity of miRNAs as biomarkers for the diagnosis of CRC.

Despite the large numbers of studies investigating plasma or serum miRNAs in patients with CRC or CAA, there still remains variation as to which significantly dysregulated miRNAs are identified. Some miRNAs were found to be significantly dysregulated in multiple studies, yet not all of these studies performed in miRNA screening prior to testing and validation, for example, miR-21, was significantly dysregulated in seven studies; however, only one of these performed initial miRNA screening. In addition, of the 28 miRNAs included in the meta-analysis, only 3 were reported as significantly dysregulated by more than 1 study: miR-21, miR-29b and miR-92.

The majority of studies were performed in either North America or South East Asia. It is possible that genetics, geography, and race may affect miRNA expression differently in these groups of patients, resulting in the observed differences in significantly dysregulated miRNAs. With the recent availability of blood-based screening tests for CRC, it is important to focus on quality and study reporting standards.

Conclusion
==========

This systematic review identifies numerous miRNAs associated with colorectal carcinogenesis. miRNAs can distinguish patients with CRC from healthy controls with high sensitivity and specificity, however; no single stand-alone miRNA has yet been identified as an ideal biomarker for the diagnosis of CRC. In order to develop a diagnostic test for the detection of CRC, we propose that a panel of miRNAs with high sensitivity and specificity should be chosen and tested in a large population of subjects. This would include a combination of the most commonly identified miRNA, those miRNA most predictive of CRC, and the most unique miRNA to CRC, in order to develop a non-invasive test with sensitivity and specificity comparable to current screening methods for CRC. In addition, standardisation of study methodology such as the use of serum samples, TaqMan qRT-PCR detection, and an external miRNA reference control should be implemented in future studies.

With deaths from CRC among the leading cause of cancer deaths worldwide, there is an emphasis to increase screening, and therefore identify early, less invasive stage of disease, to improve survival. For this purpose, miRNAs have the potential in the future to be used as a relatively non-invasive, inexpensive, blood-based marker for detection of CRC.
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![Flow diagram of the literature search process and study inclusion.](bjc201712f1){#fig1}

![**QUADAS-2 assessment.** Investigators\' assessment regarding each domain for included studies. Risk of bias and applicability concerns\' (**A**) graph and (**B**) summary.](bjc201712f2){#fig2}

![**Forest plots for studies on individual miRNA assays used in the diagnosis of CRC among the 19 studies included in the meta-analysis.** (**A**) Estimates of sensitivity. (**B**) Estimates of specificity. A full color version of this figure is available at the *British Journal of Cancer* journal online.](bjc201712f3){#fig3}

![**Analysis performed for low-risk/low-concern studies with respect to QUADAS-2 quality assessment.** (**A**) Quality sensitivity analysis. Overall sensitivity was 77% (95% CI 72--83%). (**B**) Quality specificity analysis. Overall specificity was 77% (95% CI 72--81%). A full color version of this figure is available at the *British Journal of Cancer* journal online.](bjc201712f4){#fig4}

###### Characteristics of studies included in systematic review

                                  **Study population**                                                   
  ------------- ------ --------- ---------------------- ----- --------- ----------------- -------------- --------
  Ng             2009  China              130            75   CRC          71 (42--91)       68 : 62     Plasma
                                                              Control      69 (45--85)       39 : 36      
  Huang          2010  China              100            59   CRC           61**±**11        51 : 49     Plasma
                                                              Control       58**±**12        31 : 28      
  Pu             2010  China              103            37   CRC          58 (39--84)       66 : 37     Plasma
                                                              Control      32 (17--77)       19 : 18      
  Kanaan         2012  USA                 50            50   CRC           60**±**11        21 : 29     Plasma
                                                              Control       61**±**9         21 : 29      
  Wang Q         2012  China              100            68   CRC          61 (21--84)       50 : 50     Plasma
                                                              Control      57 (36--85)       35 : 33      
  Wang B         2012  China               32            39   CRC          63 (45--80)       17 : 15     Serum
                                                              Control          46             30 : 9      
  Ahmed          2012  USA                 10             5   CRC              ---             ---       Plasma
                                                              Control          ---             ---        
  Kanaan         2013  USA                 45            26   CRC              64            28 : 17     Plasma
                                                              Control       60**±**11        11 : 15      
  Zhang G        2012  China               78            86   CRC         61.4**±**13.6      43 : 35     Plasma
                                                              Control     60.3**±**11.8      53 : 33      
  Luo            2013  Germany            130            244  CRC             67.55          70 : 60     Plasma
                                                              Control         61.93         105 : 139     
  Giraldez       2013  Spain               63            73   CRC              ---             ---       Plasma
                                                              Control         61.35          37 : 36      
  Brunet Vega    2013  Spain               30            26   CRC          68.1**±**11       18 : 12     Serum
                                                              Control     64.1**±**7.4       13 : 13      
  Liu            2013  China              200            80   CRC        57.09 (20--89)    126 :  : 74   Serum
                                                              Control    57.71 (28--89)      42 : 38      
  Yu H           2013  China               30            30   CRC              ---             ---       Serum
                                                              Control          ---             ---        
  Toiyama        2013  USA                186            53   CRC         67.5**±**7.5       106 : 80    Serum
                                                              Control      64**±**12.9       27 : 26      
  Hofsli         2013  Norway              70            20   CRC             70.5           32 : 38     Serum
                                                              Control          ⩾50           10 : 10      
  Perilli        2014  Italy               20            10   CRC              ---             ---       Plasma
                                                              Control          ---             ---        
  Basati         2014  Iran                40            40   CRC        55.35**±**10.13     21 : 19     Serum
                                                              Control    55.00**±**10.35     22 : 18      
  Zheng          2014  China              307            226  CRC             57.68         180 : 127    Serum
                                                              Control         53.15          128 : 98     
  Du             2014  China               49            49   CRC              ---             ---       Plasma
                                                              Control          ---             ---        
  Xu             2014  China               94            46   CRC             64.9           54 : 40     Plasma
                                                              Control         65.8           22 : 24      
  Zanutto        2014  Italy               65            70   CRC              ---             ---       Plasma
                                                              Control          ---             ---        
  Chen           2015  China              100            79   CRC             58.91          60 : 40     Plasma
                                                              Control         60.20          44 : 35      
  Ramzy          2015  Egypt               25            10   CRC              ---             ---       Serum
                                                              Control          ---             ---        
  Ho             2015  USA                 11            10   CRC             68.0            8 : 3      Serum
                                                              Control         54.5            4 : 6       
  Li J           2015  China              175            130  CRC             58.7           113 : 62    Serum
                                                              Control         54.1           70 : 50      
  Li L           2015  China              200            400  CRC         66.3**±**11.8      135 : 65    Plasma
                                                              Control     65.5**±**10.8    283 :  : 117   
  Fang           2015  China              111            130  CRC              60            59 : 52     Plasma
                                                              Control          ---             ---        
  Basati         2015  Iran                55            55   CRC         58.52**±**10       30 : 25     Serum
                                                              Control    57.87**±**10.15     31 : 24      
  Ghanbari       2015  Iran                61            24   CRC        64.13**±**8.67      34 : 27     Plasma
                                                              Control    61.96**±**8.67      14 : 10      
  Wang S         2015  China              124            117  CRC              64            54 : 70     Plasma
                                                              Control          43            65 : 52      
  Wang W         2016  China              268            102  CRC          58 (49--66)      151 : 117    Serum
                                                              Control      56 (48--66)         ---        
  Sun            2016  USA                227            57   CRC          55**±**7.8       119 : 108    Plasma
                                                              Control      54**±**6.3        27 : 30      
  Yu J           2016  China              165            30   CRC         60.7**±**11.6      78 : 87     Serum
                                                              Control     59.4**±**14.5      15 : 15      

Abbreviation: CRC, colorectal cancer.

###### Significantly dysregulated miRNAs in the plasma and serum of patients with CRC as compared with controls

  **miRNA**                                                                                        **Expression**                                              **Area under the curve (AUC)**          **Sensitivity**           **Specificity**  **Study**
  ------------------------------------------------------------------------------------------------ ---------------------------------------------------------- -------------------------------- -------------------------------- ----------------- -----------
  **Single miRNA**                                                                                                                                                                                                                                
  miR-17-3p                                                                                        Upregulated                                                             0.717                             64%                       70%        [@bib60]
                                                                                                                                                                           0.781                ---[a](#t2-fn2){ref-type="fn"}         ---        [@bib39]
  miR-18a                                                                                          Upregulated                                                             0.804                            73.1%                     79.1%       [@bib88]
                                                                                                                                                                            ---                              ---                       ---        [@bib5]
  miR-19a-3p                                                                                       Upregulated                                                             0.849                             ---                       ---        [@bib89]
  miR-20a                                                                                          Upregulated                                                             0.590                             46%                     73.42%       [@bib10]
  miR-21                                                                                           Upregulated                                                             0.910                             90%                       90%        [@bib35]
                                                                                                                                                                           0.850                            87.5%                     74.4%       [@bib73]
                                                                                                                                                                           0.802                             65%                       85%        [@bib42]
                                                                                                                                                                           0.927                            82.8%                     90.6%       [@bib70]
                                                                                                                                                                           0.870                             77%                       78%        [@bib3]
                                                                                                                                                                           0.877                            76.2%                     93.2%       [@bib16]
                                                                                                                                                                           0.647                             ---                       ---        [@bib85]
  miR-29a                                                                                          Upregulated                                                             0.844                             69%                      89.1%       [@bib30]
                                                                                                                                                                            ---                              ---                       ---        [@bib5]
  miR-92                                                                                           Upregulated                                                             0.885                             89%                       70%        [@bib60]
  miR-92a                                                                                                                                                                  0.838                             84%                      71.2%       [@bib30]
  miR-92a-3p                                                                                                                                                               0.786                            65.5%                     82.5%       [@bib42]
                                                                                                                                                                           0.890                             ---                       ---        [@bib89]
  miR-96                                                                                           Upregulated                                                             0.740                            65.4%                     73.3%       [@bib68]
  miR-106a                                                                                         Upregulated                                                             0.605                             74%                      44.4%       [@bib10]
                                                                                                                                                                           0.808                             ---                       ---        [@bib39]
  miR-182                                                                                          Upregulated                                                              ---                              ---                       ---        [@bib63]
  miR-200c                                                                                         Upregulated                                                             0.749                            64.1%                     73.3%       [@bib88]
  miR-206                                                                                          Upregulated                                                             0.705                             ---                       ---        [@bib79]
  miR-210                                                                                          Upregulated                                                             0.821                            74.6%                     73.5%       [@bib77]
  miR-221                                                                                          Upregulated                                                             0.606                             86%                       41%        [@bib64]
  miR-223-3p                                                                                       Upregulated                                                             0.871                             ---                       ---        [@bib89]
  miR-372                                                                                          Upregulated                                                             0.854                            81.9%                     73.3%       [@bib84]
  miR-378                                                                                          Upregulated                                                             0.796                             ---                       ---        [@bib85]
  miR-24                                                                                           Downregulated                                                           0.839                            78.38%                   83.85%       [@bib19]
  miR-26a-5p                                                                                       Downregulated                                                           0.670                             ---                       ---        [@bib22]
  miR-29b                                                                                          Downregulated                                                           0.743                            61.4%                     72.5%       [@bib39]
                                                                                                                                                                           0.870                             77%                       75%        [@bib4]
  miR-30b                                                                                          Downregulated                                                            ---                              ---                       ---        [@bib27]
  miR-142-3p                                                                                       Downregulated                                                           0.710                             ---                       ---        [@bib22]
  miR-145                                                                                          Downregulated                                                            ---                              ---                       ---        [@bib65]
                                                                                                                                                                           0.874                             ---                       ---        [@bib39]
  miR-194                                                                                          Downregulated                                                           0.850                             72%                       80%        [@bib4]
  miR-218                                                                                          Downregulated                                                            ---                              ---                       ---        [@bib83]
  miR-320a                                                                                         Downregulated                                                           0.886                            92.79%                   73.08%       [@bib19]
  miR-375                                                                                          Downregulated                                                           0.749                            76.92%                   64.63%       [@bib79]
  miR-422a                                                                                         Downregulated                                                           0.843                             ---                       ---        [@bib89]
  miR-423-5p                                                                                       Downregulated                                                           0.833                            91.89%                   70.77%       [@bib19]
  miR-601                                                                                          Downregulated                                                           0.747                            69.2%                     72.4%       [@bib75]
  miR-760                                                                                          Downregulated                                                           0.788                             80%                      72.4%       [@bib75]
  **Two miRNA panels**                                                                                                                                                                                                                            
  miR-19a, -19b                                                                                    Upregulated                                                             0.820                            78.57%                   77.36%       [@bib23]
  miR-21, -92a                                                                                     Upregulated                                                             0.847                             68%                      91.2%       [@bib42]
  miR-29a, -92a                                                                                    Upregulated                                                             0.883                             83%                      84.7%       [@bib30]
  miR-200c, -18a                                                                                   Upregulated                                                             0.839                            84.6%                     75.6%       [@bib88]
  miR-431, -139-3p                                                                                 Upregulated                                                             0.829                             91%                       57%        [@bib36]
  miR-601, -760                                                                                    Downregulated                                                           0.792                            83.3%                     69.1%       [@bib75]
  miR-375, -206                                                                                    Upregulated and Downregulated[b](#t2-fn3){ref-type="fn"}                0.846                             ---                       ---        [@bib79]
  **Three miRNA panels**                                                                                                                                                                                                                          
  miR-19a, -19b, -15b                                                                              Upregulated                                                             0.840                            78.57%                   79.25%       [@bib23]
  miR-486, -25, -1180                                                                              Upregulated                                                              ---                              ---                       ---        [@bib27]
  miR-24, -320a, -423-5p                                                                           Downregulated                                                           0.899                            92.79%                   70.77%       [@bib19]
  miR-145, -106a, -17-3p                                                                           Upregulated and Downregulated                                           0.886                            78.5%                     82.8%       [@bib39]
  miR-409-3p, -7, -93                                                                              Upregulated and Downregulated                                           0.897                             82%                       89%        [@bib76]
  **Panels with ⩾4 miRNA**                                                                                                                                                                                                                        
  miR-18a, -19a, -19b, -15b, 29a, -335                                                             Upregulated                                                           0.70--0.80                          ---                       ---        [@bib23]
  miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145                                         Upregulated                                                             0.745                             ---                       ---        [@bib46]
  miR-423-5p, -210, -720, -320a, -378, -92a, -29a, 155                                             Upregulated                                                              ---                              ---                       ---        [@bib28]
  miR-7, -17-3p, -20a, -21, -92a, -96, -183, -196a, -214                                           Upregulated                                                              ---                              ---                       ---        [@bib2]
  miR-29a, -92a, -601, -760                                                                        ---                                                                     0.943                            83.3%                     93.1%       [@bib75]
  miR-124, -127-5p, -138, -143, -146a, -222                                                        Downregulated                                                            ---                              ---                       ---        [@bib2]
  miR-106a, -143, -103, -199-3p, -151-5p, -107, -191, -423-3p, -221, -382, -409-3p, -652, let 7d   Downregulated                                                            ---                              ---                       ---        [@bib28]

Abbreviations: CRC=colorectal cancer; miRNA=microRNA.

Not reported.

Upregulated and downregulated---where the individual miRNAs were either upregulated or downregulated in CRC compared with healthy controls.
